Arie Bellde­grun's vi­sion for Gink­go comes in­to view, as the now $15B com­pa­ny teams with Bio­gen on gene ther­a­py

When Arie Bellde­grun toured Gink­go Bioworks’ fa­cil­i­ties to see whether he want­ed to take them pub­lic with his SPAC, Bellde­grun couldn’t stop talk­ing about the po­ten­tial to use Gink­go’s syn­thet­ic bi­ol­o­gy tech­nol­o­gy in cell and gene ther­a­py — an odd choice, giv­en that Gink­go had nev­er done any­thing in cell and gene ther­a­py.

On Fri­day, though, a week af­ter Gink­go and Bellde­grun’s Soar­ing Ea­gle Ac­qui­si­tion Corp. merged in a record-set­ting deal, they got in­to the game. They an­nounced an agree­ment with Bio­gen to im­prove the man­u­fac­tura­bil­i­ty of the AAV vec­tors the large biotech is de­vel­op­ing for gene ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER